A prospective randomized study on the efficacy of two nucleoside (acid) analogue against hepatitis B recurrence after liver transplantation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-PRC-10001092

Enrollment

Unknown

Registered

2010-06-02

Start date

2010-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B recurrence after liver transplantation

Interventions

1:NA plus NA

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (Long-term survival group): Hepatitis B related end-stage liver disease patients undergoing liver transplantation; Have been receiving HBIG combined nucleoside (acid) analogue treatment to prevent hepatitis B recurrence; Survival time > 3 years after liver transplantation; No recurrence of hepatitis B; Aged 18 to 65 years old; Able and willing to provide signed informed consent. (Early postoperative group): Hepatitis B related end-stage liver disease patients undergoing liver transplantation; Able and willing to provide signed informed consent; Survival time > 6 months after liver transplantation.

Exclusion criteria

Exclusion criteria: (Long-term survival group): Withdrew from the study by himself/herself; Stop HBIG and (or) nucleotides (acid) analogues to prevent recurrence of hepatitis B virus by himself/herself; Exogenous hepatitis B virus infection after liver transplantation. (Early postoperative group): Hepatitis B antigen of the donor is positive; Withdrew from the study by himself/herself; Stop HBIG and (or) nucleotides (acid) analogues to prevent recurrence of hepatitis B virus by himself/herself; Exogenous hepatitis B virus infection after liver transplantation

Design outcomes

Primary

Measure	Time frame
HBV-DNA, HBs-Ag, HBS-Ab, HBeAg, HBeAb, HBcAb, ALT, AST, TB, GGT, ALP, liver bioposy;	—

Countries

China

Contacts

Public ContactLiying Sun

sunxlx@yahoo.com.cn+86 13502038977

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026